Outcome disparities in multiple myeloma: A SEER-based comparative analysis of ethnic subgroups

Sikander Ailawadhi, Ibrahim T. Aldoss, Dongyun Yang, Pedram Razavi, Wendy Cozen, Taimur Sher, Asher A Chanan Khan

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Studies of ethnic disparities in malignancies have revealed variation in clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients of Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of MM patients from a broader range of ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult MM patients diagnosed since 1992 (n = 37 963), as patients of other ethnicities were not well represented prior to that. Overall survival (OS) and myeloma-specific survival (MSS) were compared across different ethnicities stratified by year of diagnosis, registry identification, age, sex and marital-status. Hispanics had the youngest median age at diagnosis (65 years) and Whites had the oldest (71 years) (P < 0·001). Increased age at diagnosis was an independent predictor of decreased OS and MSS. Asians had the best median OS (2·7 years) and MSS (4·1 years), while Hispanics had the worst median OS (2·4 years). These trends were more pronounced in patients ≥75 years. Cumulative survival benefit over successive years was largest among Whites (1·3 years) and smallest among Asians (0·5 years). These disparities may be secondary to multifactorial causes that need to be explored and should be considered for optimal triaging of healthcare resources.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalBritish Journal of Haematology
Volume158
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Multiple Myeloma
Epidemiology
Survival
Hispanic Americans
Registries
Marital Status
African Americans
Demography
Delivery of Health Care
Neoplasms

Keywords

  • Ethnicity
  • Hispanic
  • Multiple myeloma
  • Outcome
  • Surveillance Epidemiology and End Results

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome disparities in multiple myeloma : A SEER-based comparative analysis of ethnic subgroups. / Ailawadhi, Sikander; Aldoss, Ibrahim T.; Yang, Dongyun; Razavi, Pedram; Cozen, Wendy; Sher, Taimur; Chanan Khan, Asher A.

In: British Journal of Haematology, Vol. 158, No. 1, 07.2012, p. 91-98.

Research output: Contribution to journalArticle

@article{5e6890ae60e54293a869f4b32a9bc46d,
title = "Outcome disparities in multiple myeloma: A SEER-based comparative analysis of ethnic subgroups",
abstract = "Studies of ethnic disparities in malignancies have revealed variation in clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients of Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of MM patients from a broader range of ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult MM patients diagnosed since 1992 (n = 37 963), as patients of other ethnicities were not well represented prior to that. Overall survival (OS) and myeloma-specific survival (MSS) were compared across different ethnicities stratified by year of diagnosis, registry identification, age, sex and marital-status. Hispanics had the youngest median age at diagnosis (65 years) and Whites had the oldest (71 years) (P < 0·001). Increased age at diagnosis was an independent predictor of decreased OS and MSS. Asians had the best median OS (2·7 years) and MSS (4·1 years), while Hispanics had the worst median OS (2·4 years). These trends were more pronounced in patients ≥75 years. Cumulative survival benefit over successive years was largest among Whites (1·3 years) and smallest among Asians (0·5 years). These disparities may be secondary to multifactorial causes that need to be explored and should be considered for optimal triaging of healthcare resources.",
keywords = "Ethnicity, Hispanic, Multiple myeloma, Outcome, Surveillance Epidemiology and End Results",
author = "Sikander Ailawadhi and Aldoss, {Ibrahim T.} and Dongyun Yang and Pedram Razavi and Wendy Cozen and Taimur Sher and {Chanan Khan}, {Asher A}",
year = "2012",
month = "7",
doi = "10.1111/j.1365-2141.2012.09124.x",
language = "English (US)",
volume = "158",
pages = "91--98",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Outcome disparities in multiple myeloma

T2 - A SEER-based comparative analysis of ethnic subgroups

AU - Ailawadhi, Sikander

AU - Aldoss, Ibrahim T.

AU - Yang, Dongyun

AU - Razavi, Pedram

AU - Cozen, Wendy

AU - Sher, Taimur

AU - Chanan Khan, Asher A

PY - 2012/7

Y1 - 2012/7

N2 - Studies of ethnic disparities in malignancies have revealed variation in clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients of Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of MM patients from a broader range of ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult MM patients diagnosed since 1992 (n = 37 963), as patients of other ethnicities were not well represented prior to that. Overall survival (OS) and myeloma-specific survival (MSS) were compared across different ethnicities stratified by year of diagnosis, registry identification, age, sex and marital-status. Hispanics had the youngest median age at diagnosis (65 years) and Whites had the oldest (71 years) (P < 0·001). Increased age at diagnosis was an independent predictor of decreased OS and MSS. Asians had the best median OS (2·7 years) and MSS (4·1 years), while Hispanics had the worst median OS (2·4 years). These trends were more pronounced in patients ≥75 years. Cumulative survival benefit over successive years was largest among Whites (1·3 years) and smallest among Asians (0·5 years). These disparities may be secondary to multifactorial causes that need to be explored and should be considered for optimal triaging of healthcare resources.

AB - Studies of ethnic disparities in malignancies have revealed variation in clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients of Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of MM patients from a broader range of ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult MM patients diagnosed since 1992 (n = 37 963), as patients of other ethnicities were not well represented prior to that. Overall survival (OS) and myeloma-specific survival (MSS) were compared across different ethnicities stratified by year of diagnosis, registry identification, age, sex and marital-status. Hispanics had the youngest median age at diagnosis (65 years) and Whites had the oldest (71 years) (P < 0·001). Increased age at diagnosis was an independent predictor of decreased OS and MSS. Asians had the best median OS (2·7 years) and MSS (4·1 years), while Hispanics had the worst median OS (2·4 years). These trends were more pronounced in patients ≥75 years. Cumulative survival benefit over successive years was largest among Whites (1·3 years) and smallest among Asians (0·5 years). These disparities may be secondary to multifactorial causes that need to be explored and should be considered for optimal triaging of healthcare resources.

KW - Ethnicity

KW - Hispanic

KW - Multiple myeloma

KW - Outcome

KW - Surveillance Epidemiology and End Results

UR - http://www.scopus.com/inward/record.url?scp=84862269170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862269170&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2012.09124.x

DO - 10.1111/j.1365-2141.2012.09124.x

M3 - Article

C2 - 22533740

AN - SCOPUS:84862269170

VL - 158

SP - 91

EP - 98

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -